Kineta, RLB Holdings deal

Kineta and investment fund RLB formed JV Kineta RLB LLC to develop Kineta compounds, with an initial focus on autoimmune diseases. The partners provided undisclosed funding to the JV and are equal partners, according to Kineta. Kineta's business model involves partnering its assets at the end of Phase I, and the company doesn't currently have the ability to enter a co-development partnership. The company said that the JV allows for a broader range of partnership options, which may have greater appeal to partners and Kineta's investors, which includes RLB. Craig Phillips will be president of Kineta RLB, while remaining EVP of commercial operations at Kineta. RLB could not be reached for details. ...